Logo image of MLTX

MOONLAKE IMMUNOTHERAPEUTICS (MLTX) Stock Fundamental Analysis

USA - NASDAQ:MLTX - KY61559X1045 - Common Stock

10.63 USD
+0.34 (+3.3%)
Last: 11/7/2025, 8:00:01 PM
10.5353 USD
-0.09 (-0.89%)
After Hours: 11/7/2025, 8:00:01 PM
Fundamental Rating

2

Overall MLTX gets a fundamental rating of 2 out of 10. We evaluated MLTX against 531 industry peers in the Biotechnology industry. While MLTX seems to be doing ok healthwise, there are quite some concerns on its profitability. MLTX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

MLTX had negative earnings in the past year.
In the past year MLTX has reported a negative cash flow from operations.
MLTX had negative earnings in each of the past 5 years.
In the past 5 years MLTX always reported negative operating cash flow.
MLTX Yearly Net Income VS EBIT VS OCF VS FCFMLTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M

1.2 Ratios

With a Return On Assets value of -50.80%, MLTX perfoms like the industry average, outperforming 49.34% of the companies in the same industry.
Looking at the Return On Equity, with a value of -72.86%, MLTX is in line with its industry, outperforming 54.99% of the companies in the same industry.
Industry RankSector Rank
ROA -50.8%
ROE -72.86%
ROIC N/A
ROA(3y)-32.25%
ROA(5y)-130.19%
ROE(3y)-45.35%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MLTX Yearly ROA, ROE, ROICMLTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -500 -1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MLTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MLTX Yearly Profit, Operating, Gross MarginsMLTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

4

2. Health

2.1 Basic Checks

The number of shares outstanding for MLTX has been increased compared to 1 year ago.
MLTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MLTX Yearly Shares OutstandingMLTX Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 20M 40M 60M
MLTX Yearly Total Debt VS Total AssetsMLTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of 1.14, we must say that MLTX is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.14, MLTX is in the better half of the industry, outperforming 63.65% of the companies in the same industry.
A Debt/Equity ratio of 0.26 indicates that MLTX is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.26, MLTX is doing worse than 69.30% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF N/A
Altman-Z 1.14
ROIC/WACCN/A
WACCN/A
MLTX Yearly LT Debt VS Equity VS FCFMLTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

MLTX has a Current Ratio of 8.50. This indicates that MLTX is financially healthy and has no problem in meeting its short term obligations.
MLTX's Current ratio of 8.50 is fine compared to the rest of the industry. MLTX outperforms 76.65% of its industry peers.
A Quick Ratio of 8.50 indicates that MLTX has no problem at all paying its short term obligations.
The Quick ratio of MLTX (8.50) is better than 76.84% of its industry peers.
Industry RankSector Rank
Current Ratio 8.5
Quick Ratio 8.5
MLTX Yearly Current Assets VS Current LiabilitesMLTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

1

3. Growth

3.1 Past

MLTX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -157.36%.
EPS 1Y (TTM)-157.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-96.43%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

MLTX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.49% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-77.76%
EPS Next 2Y-40.52%
EPS Next 3Y-22.53%
EPS Next 5Y10.49%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MLTX Yearly Revenue VS EstimatesMLTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
MLTX Yearly EPS VS EstimatesMLTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MLTX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MLTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MLTX Price Earnings VS Forward Price EarningsMLTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MLTX Per share dataMLTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

A cheap valuation may be justified as MLTX's earnings are expected to decrease with -22.53% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-40.52%
EPS Next 3Y-22.53%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MLTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MOONLAKE IMMUNOTHERAPEUTICS

NASDAQ:MLTX (11/7/2025, 8:00:01 PM)

After market: 10.5353 -0.09 (-0.89%)

10.63

+0.34 (+3.3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2025-11-05/bmo
Earnings (Next)02-24 2026-02-24/bmo
Inst Owners95.1%
Inst Owner Change-2.95%
Ins Owners11.02%
Ins Owner Change0.13%
Market Cap682.76M
Revenue(TTM)N/A
Net Income(TTM)-210.50M
Analysts87.5
Price Target22.03 (107.24%)
Short Float %8.66%
Short Ratio0.92
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-20.5%
Min EPS beat(2)-22.75%
Max EPS beat(2)-18.26%
EPS beat(4)1
Avg EPS beat(4)-10.31%
Min EPS beat(4)-22.75%
Max EPS beat(4)17.89%
EPS beat(8)2
Avg EPS beat(8)-8.49%
EPS beat(12)6
Avg EPS beat(12)0.35%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-69.91%
PT rev (3m)-71.97%
EPS NQ rev (1m)-0.64%
EPS NQ rev (3m)-18.92%
EPS NY rev (1m)-0.13%
EPS NY rev (3m)-14.67%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.36
P/tB 2.36
EV/EBITDA N/A
EPS(TTM)-3.32
EYN/A
EPS(NY)-3.73
Fwd EYN/A
FCF(TTM)-2.89
FCFYN/A
OCF(TTM)-2.89
OCFYN/A
SpS0
BVpS4.5
TBVpS4.5
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -50.8%
ROE -72.86%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-32.25%
ROA(5y)-130.19%
ROE(3y)-45.35%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 6.65%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.5
Quick Ratio 8.5
Altman-Z 1.14
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)797.86%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-157.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-96.43%
EPS Next Y-77.76%
EPS Next 2Y-40.52%
EPS Next 3Y-22.53%
EPS Next 5Y10.49%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-111.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-70.43%
EBIT Next 3Y-18.11%
EBIT Next 5YN/A
FCF growth 1Y-342.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-341.9%
OCF growth 3YN/A
OCF growth 5YN/A

MOONLAKE IMMUNOTHERAPEUTICS / MLTX FAQ

Can you provide the ChartMill fundamental rating for MOONLAKE IMMUNOTHERAPEUTICS?

ChartMill assigns a fundamental rating of 2 / 10 to MLTX.


What is the valuation status of MOONLAKE IMMUNOTHERAPEUTICS (MLTX) stock?

ChartMill assigns a valuation rating of 0 / 10 to MOONLAKE IMMUNOTHERAPEUTICS (MLTX). This can be considered as Overvalued.


Can you provide the profitability details for MOONLAKE IMMUNOTHERAPEUTICS?

MOONLAKE IMMUNOTHERAPEUTICS (MLTX) has a profitability rating of 1 / 10.


Can you provide the financial health for MLTX stock?

The financial health rating of MOONLAKE IMMUNOTHERAPEUTICS (MLTX) is 4 / 10.